| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
The primary molecular target of Biotin-DADOO TFA is primary amine (-NH2) groups present on proteins, peptides, antibodies, and other biomolecules, particularly lysine side chains and N-termini. The biotin moiety of the reagent binds with exceptionally high affinity (Kd ≈ 10-¹⁴ to 10-¹⁵ M) to avidin and streptavidin proteins. Biotin-DADOO TFA serves as a biotinylating agent, enabling the attachment of biotin tags to target molecules. The DADOO (diaminodioxaoctane) spacer arm provides flexibility and reduces steric hindrance between the biotin tag and the conjugated molecule, preserving biological activity of labeled molecules.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Biotin-DADOO TFA is an effective biotinylating reagent for synthesizing biotin-labeled conjugates for use in enzyme immunoassays (EIAs). The biotin-estradiol conjugates synthesized using Biotin-DADOO TFA enable the sensitive detection of estradiol in plasma samples via competitive immunoassay, where estradiol competes with the biotin-estradiol conjugate for binding to anti-estradiol antibodies. The DADOO linker provides adequate spacing to avoid steric interference with antibody recognition. No direct enzyme inhibition or receptor activation activity has been reported for this reagent.
|
| ln Vivo |
No dedicated in vivo pharmacological or therapeutic activity data exist for Biotin-DADOO TFA. It is exclusively a research reagent for in vitro and ex vivo biotinylation applications. When used to prepare biotinylated conjugates for immunoassays, such conjugates may be administered to animals in pharmacokinetic studies, but the reagent itself is not directly dosed in vivo. For imaging or biodistribution studies, biotinylated conjugates prepared with Biotin-DADOO TFA can be tracked via avidin or streptavidin probes.
|
| Enzyme Assay |
No specific enzyme/receptor binding assay protocol exists for Biotin-DADOO TFA itself. For its biotinylation function, a typical conjugation protocol: Dissolve the target molecule containing primary amine(s) (e.g., antibody, estradiol derivative with amino group) in reaction buffer (0.1 M sodium bicarbonate, pH 8.0-8.5, or PBS pH 7.2-7.4). Dissolve Biotin-DADOO TFA in DMSO or DMF (10-100 mM stock). Mix the target solution with 5-20 fold molar excess of biotin reagent. Incubate for 30-60 minutes at room temperature or 2-12 hours at 4degC. Desalt or dialyze against PBS to remove unincorporated biotin. The DADOO spacer provides a 14-atom flexible arm. Confirm biotin incorporation by HABA assay or streptavidin blot.
|
| Cell Assay |
No standard cell-based viability, proliferation, or functional assays exist for Biotin-DADOO TFA as a bioactive molecule. When incorporated into biotinylated conjugates for cellular studies, these conjugates are incubated with cells or tissue sections. Subsequent detection is typically performed using fluorophore-labeled streptavidin or avidin (e.g., FITC-streptavidin, HRP-streptavidin). For in vitro labeling of cellular proteins, cells are lysed in RIPA buffer containing protease inhibitors, and the lysate is incubated with biotinylated probes. Streptavidin-coated magnetic beads or agarose resin is used for pull-down of biotinylated targets, followed by Western blotting or mass spectrometry.
|
| Animal Protocol |
No dedicated in vivo animal study protocols exist for Biotin-DADOO TFA as a therapeutic agent, as it is exclusively a labeling reagent. For validation of biotin-estradiol conjugates in animal models, a typical protocol: Estradiol-deficient or gonadecomized rats are administered estradiol (or biotin-estradiol conjugate) at 0.5-5 microg per animal, and serum samples are collected at various time points (0, 1, 2, 4, 8, 24 hours). Biotin-estradiol levels are measured via competitive ELISA using an anti-estradiol antibody coated on 96-well plates, with HRP-streptavidin detection. This protocol validates the utility of the conjugate in estradiol quantification but does not evaluate the reagent's intrinsic activity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Biotin-DADOO TFA are not available as the compound is used as a reagent for ex vivo labeling, not as an administered drug. The DADOO (diaminodioxaoctane) linker is designed to be non-toxic, water-soluble, and non-immunogenic, providing a hydrophilic spacer that improves water solubility compared to traditional hydrocarbon linkers. The TFA counterion is typically removed during purification of biotinylated conjugates. Unconjugated Biotin-DADOO TFA is water-insoluble in its TFA salt form but becomes soluble after conjugation.
|
| Toxicity/Toxicokinetics |
No dedicated toxicology data for Biotin-DADOO TFA are publicly available. The reagent is for research use only and should be handled with standard laboratory precautions. The TFA counterion is moderately corrosive and may cause skin and eye irritation. Avoid inhalation, ingestion, and skin contact. Wear appropriate PPE (nitrile gloves, safety goggles, lab coat). In case of skin contact, wash thoroughly with soap and water. For eye exposure, rinse with copious amounts of water for 15 minutes and seek medical attention if irritation persists. Biotin-DADOO TFA is not intended for human or veterinary use.
|
| References | |
| Additional Infomation |
Biotin-DADOO TFA is a research-use only reagent with no approved clinical or therapeutic applications. Its primary applications include: (1) Biotinylation of antibodies, proteins, peptides, and small molecules; (2) Synthesis of biotin-estradiol conjugates for plasma estradiol quantification by enzyme immunoassay; (3) Biotin labeling of CMC thiosulfate; (4) Multifunctional dye for tracking biomolecules and evaluating cell functions. The DADOO spacer is a proprietary chemical entity (diaminodioxaoctane) that reduces steric hindrance and improves binding to avidin/streptavidin.
|
| Molecular Formula |
C18H31F3N4O6S
|
|---|---|
| Molecular Weight |
488.52
|
| Exact Mass |
488.192
|
| CAS # |
194920-57-5
|
| Related CAS # |
Biotin-DADOO; 138529-46-1
|
| PubChem CID |
71311743
|
| Appearance |
ointment
|
| LogP |
1.963
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
32
|
| Complexity |
510
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)NCCOCCOCCN)NC(=O)N2.C(=O)(C(F)(F)F)O
|
| InChi Key |
SJXUUAFYSXSFNA-HZPCBCDKSA-N
|
| InChi Code |
InChI=1S/C16H30N4O4S.C2HF3O2/c17-5-7-23-9-10-24-8-6-18-14(21)4-2-1-3-13-15-12(11-25-13)19-16(22)20-15;3-2(4,5)1(6)7/h12-13,15H,1-11,17H2,(H,18,21)(H2,19,20,22);(H,6,7)/t12-,13-,15-;/m0./s1
|
| Chemical Name |
5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]pentanamide;2,2,2-trifluoroacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0470 mL | 10.2350 mL | 20.4700 mL | |
| 5 mM | 0.4094 mL | 2.0470 mL | 4.0940 mL | |
| 10 mM | 0.2047 mL | 1.0235 mL | 2.0470 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
